{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:03Z","timestamp":1792512123060,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pituitary adenomas (PA) are benign neoplasms treated by resection. Gross total resection is limited by extrasellar expansion in proximity to critical neurovascular structures. Residual tumor remains at risk of progression, with serious consequences such as optic compression or hormone hypersecretion. Adjuvant radiotherapy (RT) offers a rescue modality for both, impeding regrowth and hormonal relapse. Proton radiotherapy (PRT), owing to its favorable dose distribution and reduced exit dose through the Bragg peak, further expands the armamentarium of conventional RT modalities in cases of extrasellar macroadenomas in contact with vulnerable organs at risk. Hence, the present study provides initial evidence on the efficacy and toxicity of adjuvant PRT and offers insight into the decision-making criteria for selecting PRT over photon-based techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adjuvant PRT applied for 22 residual PA including 16 non-functioning- (NFPA) and 6 functioning PA (FPA) at a large particle-therapy center, who were reviewed for local tumor control, toxicity, hormone status and visual function. Assessment of PRT response accounted for neuro-oncology criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a median follow up of 65 months 5-year local tumor control rate of PA (FPA and NFPA) and hormone control rate of FPA was 100%. Secondary hypopituitarism after PRT was rare (1\/22). Despite treatment escalation with PRT, stable endocrine status during follow-up enabled significant reductions in required glucocorticoid supplementation. Visual improvement was reported in 64%. Toxicity was limited, with fatigue and headache being most frequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adjuvant PRT for complex residual PA is efficacious and safe for treating residual disease in extrasellar expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Importance of the study<\/jats:title>\n                    <jats:p>Pituitary adenomas (PAs) with extrasellar extension in proximity to vulnerable neurovascular tissue or brain parenchyma carry risk of residual tumor after resection that is not amenable to further safe resection. Subsequent tumor regrowth may compress adjacent neurovascular structures resulting in frequent sequelae such as visual deterioration or central nerve palsies. Persistent hormone-secreting adenoma may further sustain endocrine dysregulation. Adjuvant radiation therapy represents an important treatment strategy to impede regrowth while minimizing toxicity to surrounding critical structures, thus achieving durable visual improvement and long-term hormonal control. Proton radiotherapy (PRT) may further improve the therapeutic ratio by exploiting its steep dose gradient and highly conformal dose distribution to enhance normal tissue sparing without compromising tumor control in selected complex PA. Therefore, the present study reports experience with adjuvant PRT for complex residual PA, demonstrating 5-year local tumor control of 100%, visual improvement in 64%, and stable hormone levels in 95%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05669-2","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:57:50Z","timestamp":1781233070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults \u2013 a retrospective, single institute experience"],"prefix":"10.1007","volume":"178","author":[{"given":"Fabian J. K.","family":"Allmendinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Regnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kozyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Englert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Wickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Mose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tessonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro M.","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Adena-Eichkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"5","key":"5669_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jocn.2014.01.005","volume":"21","author":"S Ogra","year":"2014","unstructured":"Ogra S, Nichols AD, Stylli S, Kaye AH, Savino PJ, Danesh-Meyer HV (2014) Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. J Clin Neurosci 21(5):735\u2013740","journal-title":"J Clin Neurosci"},{"issue":"12","key":"5669_CR2","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1038\/s41433-024-03187-x","volume":"38","author":"MTM Wang","year":"2024","unstructured":"Wang MTM, Meyer JA, Danesh-Meyer HV (2024) Neuro-ophthalmic evaluation and management of pituitary disease. Eye (Lond) 38(12):2279\u20132288","journal-title":"Eye (Lond)"},{"issue":"4","key":"5669_CR3","doi-asserted-by":"publisher","first-page":"bvaa021","DOI":"10.1210\/jendso\/bvaa021","volume":"4","author":"PU Freda","year":"2020","unstructured":"Freda PU, Bruce JN, Khandji AG, Jin Z, Hickman RA, Frey E et al (2020) Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study. J Endocr Soc 4(4):bvaa021","journal-title":"J Endocr Soc"},{"issue":"10","key":"5669_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M et al (2017) Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24(10):505\u2013518","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"5669_CR5","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1210\/jc.2005-0070","volume":"90","author":"YS Woo","year":"2005","unstructured":"Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I et al (2005) Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 90(8):4963\u20134969","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5669_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3171\/2018.11.JNS181238","volume":"132","author":"AS Little","year":"2020","unstructured":"Little AS, Kelly DF, White WL, Gardner PA, Fernandez-Miranda JC, Chicoine MR et al (2020) Results of a prospective multicenter controlled study comparing surgical outcomes of microscopic versus fully endoscopic transsphenoidal surgery for nonfunctioning pituitary adenomas: the Transsphenoidal Extent of Resection (TRANSSPHER) Study. J Neurosurg 132(4):1043\u20131053","journal-title":"J Neurosurg"},{"issue":"5","key":"5669_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11102-019-00976-6","volume":"22","author":"M Buchy","year":"2019","unstructured":"Buchy M, Lapras V, Rabilloud M, Vasiljevic A, Borson-Chazot F, Jouanneau E et al (2019) Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification. Pituitary 22(5):467\u2013475","journal-title":"Pituitary"},{"issue":"4","key":"5669_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000339823","volume":"96","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC et al (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4):333\u2013342","journal-title":"Neuroendocrinology"},{"issue":"6","key":"5669_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4132\/jptm.2016.06.30","volume":"50","author":"JS Kim","year":"2016","unstructured":"Kim JS, Lee YS, Jung MJ, Hong YK (2016) The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence. J Pathol Transl Med 50(6):419\u2013425","journal-title":"J Pathol Transl Med"},{"issue":"5","key":"5669_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0360-3016(01)01535-8","volume":"50","author":"S Milker-Zabel","year":"2001","unstructured":"Milker-Zabel S, Debus J, Thilmann C, Schlegel W, Wannenmacher M (2001) Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland. Int J Radiat Oncol Biol Phys 50(5):1279\u20131286","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5669_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1748-717X-8-18","volume":"8","author":"S Rieken","year":"2013","unstructured":"Rieken S, Habermehl D, Welzel T, Mohr A, Lindel K, Debus J et al (2013) Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas. Radiat Oncol 8:18","journal-title":"Radiat Oncol"},{"key":"5669_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1748-717X-6-169","volume":"6","author":"DC Weber","year":"2011","unstructured":"Weber DC, Momjian S, Pralong FP, Meyer P, Villemure JG, Pica A (2011) Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma. Radiat Oncol 6:169","journal-title":"Radiat Oncol"},{"issue":"2","key":"5669_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1227\/NEU.0b013e31821bc44e","volume":"69","author":"R Gopalan","year":"2011","unstructured":"Gopalan R, Schlesinger D, Vance ML, Laws E, Sheehan J (2011) Long-term outcomes after Gamma Knife radiosurgery for patients with a nonfunctioning pituitary adenoma. Neurosurgery 69(2):284\u2013293","journal-title":"Neurosurgery"},{"issue":"1","key":"5669_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00701-024-06296-4","volume":"166","author":"F De Nigris Vasconcellos","year":"2024","unstructured":"De Nigris Vasconcellos F, Vilela MAD, Garcia Torrico F, Scalise MA, Vargas VPS, Mendieta CD et al (2024) Stereotactic radiosurgery for recurrent\/residual nonfunctioning pituitary adenoma: a single-arm systematic review and meta-analysis. Acta Neurochir (Wien) 166(1):392","journal-title":"Acta Neurochir (Wien)"},{"issue":"11","key":"5669_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/cancers10110401","volume":"10","author":"S Adeberg","year":"2018","unstructured":"Adeberg S, Harrabi SB, Bougatf N, Verma V, Windisch P, Bernhardt D et al (2018) Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location. Cancers (Basel) 10(11):401","journal-title":"Cancers (Basel)"},{"issue":"8","key":"5669_CR16","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1210\/jc.2011-0306","volume":"96","author":"NM Appelman-Dijkstra","year":"2011","unstructured":"Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz NR, Romijn JA et al (2011) Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab 96(8):2330\u20132340","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"5669_CR17","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3171\/2012.2.JNS111630","volume":"116","author":"CP Cifarelli","year":"2012","unstructured":"Cifarelli CP, Schlesinger DJ, Sheehan JP (2012) Cranial nerve dysfunction following Gamma Knife surgery for pituitary adenomas: long-term incidence and risk factors. J Neurosurg 116(6):1304\u20131310","journal-title":"J Neurosurg"},{"issue":"4","key":"5669_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2176\/nmc.43.213","volume":"43","author":"M Hoshi","year":"2003","unstructured":"Hoshi M, Hayashi T, Kagami H, Murase I, Nakatsukasa M (2003) Late bilateral temporal lobe necrosis after conventional radiotherapy. Neurol Med Chir (Tokyo) 43(4):213\u2013216","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"3","key":"5669_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.0004-8461.2003.01237.x","volume":"48","author":"A Bhansali","year":"2004","unstructured":"Bhansali A, Banerjee AK, Chanda A, Singh P, Sharma SC, Mathuriya SN et al (2004) Radiation-induced brain disorders in patients with pituitary tumours. Australas Radiol 48(3):339\u2013346","journal-title":"Australas Radiol"},{"issue":"12","key":"5669_CR20","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/neuonc\/noae133","volume":"26","author":"C Dumot","year":"2024","unstructured":"Dumot C, Mantziaris G, Dayawansa S, Brantley C, Lee CC, Yang HC et al (2024) Risk of new tumor, carotid stenosis, and stroke after stereotactic radiosurgery for pituitary tumor: A multicenter study of 2254 patients with imaging follow-up. Neuro Oncol 26(12):2328\u20132338","journal-title":"Neuro Oncol"},{"issue":"4","key":"5669_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4183\/aeb.2017.476","volume":"13","author":"ML Gheorghiu","year":"2017","unstructured":"Gheorghiu ML, Fleseriu M (2017) Stereotactic Radiation Therapy in Pituitary Adenomas, Is It Better Than Conventional Radiation Therapy? Acta Endocrinol (Buchar) 13(4):476\u2013490","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"9596","key":"5669_CR22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457","journal-title":"Lancet"},{"issue":"3 Suppl","key":"5669_CR23","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB et al (2010) Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76(3 Suppl):S3\u20139","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5669_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COC.0000000000000014","volume":"39","author":"S Scheick","year":"2016","unstructured":"Scheick S, Amdur RJ, Kirwan JM, Morris CG, Mendenhall WM, Roper S et al (2016) Long-term Outcome After Fractionated Radiotherapy for Pituitary Adenoma: The Curse of the Secretory Tumor. Am J Clin Oncol 39(1):49\u201354","journal-title":"Am J Clin Oncol"},{"key":"5669_CR25","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/j.wneu.2023.09.067","volume":"180","author":"AV Sathe","year":"2023","unstructured":"Sathe AV, Siu A, Kang KC, Kayne A, Vinjamuri S, Kelly P et al (2023) Early Versus Delayed Fractionated Stereotactic Radiotherapy for Nonfunctioning Pituitary Adenoma. World Neurosurg 180:e317\u2013e23","journal-title":"World Neurosurg"},{"issue":"3","key":"5669_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ijrobp.2014.06.068","volume":"90","author":"DA Wattson","year":"2014","unstructured":"Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB et al (2014) Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 90(3):532\u2013539","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5669_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11060-024-04864-3","volume":"171","author":"I Kim","year":"2025","unstructured":"Kim I, Yan M, Sourour M, Heaton R, Faulkner C, Kalyvas A et al (2025) Pituitary neuroendocrine tumors treated with stereotactic radiosurgery. J Neurooncol 171(2):423\u2013430","journal-title":"J Neurooncol"},{"issue":"3","key":"5669_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11060-018-2925-2","volume":"139","author":"CC Shen","year":"2018","unstructured":"Shen CC, You WC, Sun MH, Lee SD, Tsou HK, Chen YJ et al (2018) Outcome of partially irradiated recurrent nonfunctioning pituitary macroadenoma by gamma knife radiosurgery. J Neurooncol 139(3):767\u2013775","journal-title":"J Neurooncol"},{"issue":"1","key":"5669_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13014-025-02751-3","volume":"21","author":"RM Hemaidia","year":"2025","unstructured":"Hemaidia RM, Cebula H, Goichot B, Noel G (2025) Potentially radiation-induced late toxicity after irradiation of pituitary adenoma, a retrospective dosimetric study. Radiat Oncol 21(1):5","journal-title":"Radiat Oncol"},{"issue":"3","key":"5669_CR30","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s11060-025-05228-1","volume":"175","author":"A Brand","year":"2025","unstructured":"Brand A, Agolli L, Tas KT, Lishwiski P, Schymalla M, Zink K et al (2025) Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience. J Neurooncol 175(3):1039\u20131050","journal-title":"J Neurooncol"},{"issue":"6","key":"5669_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1365-2265.2002.01570.x","volume":"57","author":"M Brada","year":"2002","unstructured":"Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B (2002) Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 57(6):713\u2013717","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"5669_CR32","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1210\/jc.2002-020526","volume":"87","author":"EM Erfurth","year":"2002","unstructured":"Erfurth EM, Bulow B, Svahn-Tapper G, Norrving B, Odh K, Mikoczy Z et al (2002) Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 87(11):4892\u20134899","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"5669_CR33","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ijrobp.2006.09.049","volume":"67","author":"AC n den Bergh","year":"2007","unstructured":"n den Bergh AC, Schoorl MA, van der Sluiter WJ, Hoving EW et al (2007) Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 67(3):863\u2013869","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5669_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2265.2005.02199.x","volume":"62","author":"G Minniti","year":"2005","unstructured":"Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F et al (2005) The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 62(2):210\u2013216","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"28","key":"5669_CR35","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1200\/JCO.2018.78.1492","volume":"36","author":"RE Vatner","year":"2018","unstructured":"Vatner RE, Niemierko A, Misra M, Weyman EA, Goebel CP, Ebb DH et al (2018) Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors. J Clin Oncol 36(28):2854\u20132862","journal-title":"J Clin Oncol"},{"issue":"3","key":"5669_CR36","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB et al (2010) Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiation Oncology* Biology* Phys 76(3):S3\u2013S9","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"2","key":"5669_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0360-3016(97)00335-0","volume":"39","author":"MW McCord","year":"1997","unstructured":"McCord MW, Buatti JM, Fennell EM, Mendenhall WM, Marcus RB Jr., Rhoton AL et al (1997) Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 39(2):437\u2013444","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5669_CR38","first-page":"vdae160","volume":"6","author":"MY Deng","year":"2024","unstructured":"Deng MY, Rauh S, Anil G, Lischalk JW, Hahnemann L, Eichkorn T et al (2024) Analysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma. Neurooncol Adv 6(1):vdae160","journal-title":"Neurooncol Adv"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05669-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:36:50Z","timestamp":1782805010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05669-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5669"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05669-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study conduct was in accordance with the Declaration of Helsinki. Ethics approval for data collection and research was granted by the Institutional Ethics Review Board (IRB) under project number S832\/2018.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent to participate was waived by the Institutional Ethics Review Board (IRB), as the studies conducted under this ethics approval were restricted to a retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The requirement for consent for publication of anonymized images was waived by the Institutional Ethics Review Board (IRB), as all images were fully anonymized and used exclusively within the scope of the approved retrospective study design.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. R. received a grant by Accuray. S. M. K. is a consultant for Brainlab (Munich), Ulrich Medical (Ulm) and Need Inc. (Santa Monica), and shareholder of Need Inc. (Santa Monica). J. D. received honorary from RaySearch Laboratories, Vision RT Limited, Merck Serono, Siemens Healthcare, PTW-Freiburg Dr. Pychlau, and Accuray Incorporated. J. D. is the CEO of the Heidelberg Ion Beam Therapy Center (HIT), and a member of the Board of Directors at the Heidelberg University Hospital.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}